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Abstract
Background: The evidence on the economic burden of cardiovascular disease (CVD) in low- and middle- income
countries (LMICs) remains scarce. We conducted a comprehensive systematic review to establish the magnitude
and knowledge gaps in relation to the economic burden of CVD and hypertension on households, health systems
and the society.
Methods: We included studies using primary or secondary data to produce original economic estimates of the
impact of CVD. We searched sixteen electronic databases from 1990 onwards without language restrictions. We
appraised the quality of included studies using a seven-question assessment tool.
Results: Eighty-three studies met the inclusion criteria, most of which were single centre retrospective cost studies
conducted in secondary care settings. Studies in China, Brazil, India and Mexico contributed together 50% of the
total number of economic estimates identified. The quality of the included studies was generally low. Reporting
transparency, particularly for cost data sources and results, was poor. The costs per episode for hypertension and
generic CVD were fairly homogeneous across studies; ranging between $500 and $1500. In contrast, for coronary
heart disease (CHD) and stroke cost estimates were generally higher and more heterogeneous, with several estimates
in excess of $5000 per episode. The economic perspective and scope of the study appeared to impact cost estimates
for hypertension and generic CVD considerably less than estimates for stroke and CHD. Most studies reported monthly
costs for hypertension treatment around $22. Average monthly treatment costs for stroke and CHD ranged between
$300 and $1000, however variability across estimates was high. In most LMICs both the annual cost of care and the
cost of an acute episode exceed many times the total health expenditure per capita.
Conclusions: The existing evidence on the economic burden of CVD in LMICs does not appear aligned with
policy priorities in terms of research volume, pathologies studied and methodological quality. Not only is more
economic research needed to fill the existing gaps, but research quality needs to be drastically improved. More
broadly, national-level studies with appropriate sample sizes and adequate incorporation of indirect costs need
to replace small-scale, institutional, retrospective cost studies.
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Background
Globally, non-communicable diseases (NCDs) account for
more than 60% of disability-adjusted life years (DALYs),
70% of deaths and more than 80% of years lived with dis-
ability (YLD) [1, 2]. Cardiovascular disease (CVD) repre-
sents 24% of NCD-related DALYs, with ischemic heart
disease and cerebrovascular disease the two major causes
of disability globally. Although age-standardised CVDmor-
tality rates have been declining globally by 14.5% between
2006 and 2016 [3], the burden of CVD remains dispropor-
tionately larger in low- and middle-income countries
(LMICs) compared to high-income countries (HICs) as
more than 80% of CVD deaths occur in LMICs [4–6].
Moreover, CVD affects working age populations much
more in LMICs compared to HICs. For example, in
Sub-Saharan Africa half of cardiovascular deaths occur in
the 30–69 years age group, at least ten years earlier than
in HICs [7]. The total economic loss due to CVD in
LMICs was estimated to amount to $3.7 trillion (2010) be-
tween 2011 and 2015, representing approximately half the
NCD economic burden and 2% of Gross Domestic Prod-
uct (GDP) across LMICs [8].
Despite high-level political commitment to improve
cardiovascular disease outcomes by 2025 [9], most coun-
tries are off course to meet the targets [10]. In many
LMICs, particularly in the poorest settings, even meeting
all the globally adopted risk factor targets may not be
sufficient to achieve the global target of 25% reduction
in CVD mortality by 2025 [11]. The challenges of health
systems in LMICs – insufficient health spending, poor
governance, inefficient care delivery systems, focus on
curative care at the expense of prevention, to name just
a few factors – have been suggested to contribute to the
CVD burden much more than the risk factor levels, which
remain low in LMICs compared to HICs [12]. For ex-
ample, CVD secondary prevention medicines remain un-
available and unaffordable in many of these countries [13].
Disability caused by CVD has economic consequences
at multiple levels: individual, household, economic agents,
public institutions, government and the society as a whole.
Not only is this burden expected to increase in the future
[14], but LMICs will incur an increasing share of this bur-
den due to population growth, ageing and globalization.
The economic impact of CVD on households, health
systems and national incomes in LMICs may jeopardise
the ongoing poverty reduction initiatives [15, 16]. Given
the centrality of advocacy efforts towards governments by
professionals and patients for improving outcomes in
LMICs [12], the importance of good quality economic
data is undisputed. However, the available economic mod-
elling studies providing estimates on the economic burden
of CVD in LMICs [17, 18] were informed by selective
literature reviews and the existing economic data appear
to be insufficient and of questionable quality [19].
Our objective was to address this knowledge gap by
synthesising the available data on the economic burden
of CVD and hypertension in LMICs to households, the
health system and society. To this end, we systematically
reviewed the existing evidence as part of a larger review
of the economic burden of seven major NCD categories
in LMICs (cardiovascular disease, diabetes, respiratory
disease, cancer, neurological disease, psychiatric disorders
and musculoskeletal disorders). The findings of this CVD
and hypertension review aim to inform the formulation
and refinement of policy and research objectives in this
area, as well as to synthesize available data for future eco-
nomic modelling exercises.
Methods
The systematic review was conducted according to a
pre-specified protocol available from the authors upon
request. The review is registered on the PROSPERO regis-
ter of systematic reviews (ID CRD42014005346). The re-
view is reported according to the PRISMA statement [20].
Search strategy and selection criteria
We included studies using primary or secondary data to
produce original economic estimates of the impact of CVD.
For the purpose of this review, we included cardiovascular
disorders together with hypertension as the leading CVD
risk factor [21] – other CVD risk factors (e.g. smoking, dia-
betes, cholesterol) were excluded. Specifically, we included
observational designs with a cost collection component,
cost-of-illness studies, and economic modelling studies.
Studies reporting any microeconomic outcome expressed
in monetary units (e.g. cost of disease management per pa-
tient year, nationwide costs of disease management per
year) or macroeconomic outcome (e.g. cost of disease as
%GDP) were included. The only non-monetary microeco-
nomic outcome accepted was productive time lost due to
illness (e.g. number of days off work). Multi-country stud-
ies referring to a mix of LMICs and HICs were included
only subject to providing explicit and detailed eco-
nomic estimates for the considered LMICs. The follow-
ing categories of sources were excluded: literature
reviews, policy papers, editorials, commentaries, opin-
ion pieces, and economic evaluation studies.
We searched 16 electronic databases from 1990 onwards:
MEDLINE, MEDLINE In-Process and Other Non-Indexed
Citations (Ovid); EMBASE; NHS Economic Evaluation
Database (NHSEED); EconLit; Cochrane Central Register
of Controlled Trials (CENTRAL); Cochrane Database of
Abstracts of Reviews of Effects (DARE); PsycInfo (Ovid);
Latin American and Caribbean Health Sciences Literature
database (LILACS); MedCarib; Africa-Wide Information;
Global Health; Index Medicus for the South-East Region
(IMSER); Index Medicus for the Eastern Mediterranean
Region (IMSEAR); Western Pacific Region Index Medicus
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(WPRIM); and the New York Academy of Medicine Grey
Literature Report. In addition, we searched the websites of
the World Health Organization, the World Bank, the
World Economic Forum, and NCD Alliance for relevant
reports. We also hand-searched the reference lists of in-
cluded studies for further relevant sources. No language
restrictions applied. The initial search was conducted in
August 2013 and updated in June 2015.
Our search strategy (presented in full in Additional file 1)
combined three groups of search terms: 1) CVD and hyper-
tension; 2) LMICs - 139 LMICs were identified based
on the World Bank income classification of countries
and searched individually, as well as with generic terms
such as ‘low-income’ and ‘middle-income’; and 3) eco-
nomic burden - the following generic search terms were
used: burden of illness; cost of illness; health expenditure;
costs and cost analysis; absenteeism; productivity loss;
poverty; income; economic modelling; economic burden;
resource utilization; employment; labour.
Study selection followed a three-stage process: 1) two
independent reviewers performed title & abstract screen-
ing and excluded irrelevant studies; 2) two independent
reviewers screened the full-text articles against the inclu-
sion/exclusion criteria; and 3) the reference lists of in-
cluded studies were hand-searched to identify any other
relevant publications. The remaining studies at the end of
Stage 2 and any studies identified in Stage 3 were included
in the review. At all stages disagreements between re-
viewers were discussed and resolved consensually. If ne-
cessary, the opinion of a third reviewer was elicited.
Quality assessment and data extraction
We appraised the quality of included studies using a
seven-question quality assessment tool developed for the
purpose of this study (Additional file 2). The tool focussed
on two aspects: the design of the economic study, inspired
by the CHEERS (Consolidated Health Economic Evaluation
Reporting Standards) Statement [22]; and, if applicable, the
design of the epidemiological study alongside which the
economic study was conducted.
We extracted data on 1) methodological characteristics
of studies: geographical setting and any relevant contextual
information; scope (institutional; regional; national; inter-
national); disease area(s); economic perspective (provider/
payer/societal/other); type of study design (Table 1);
population characteristics; study design characteristics;
study duration/time horizon; type(s) of economic estimates
reported; and 2) economic estimates, by cost component
(direct/indirect – the latter comprising productivity costs
and costs associated with complications and comorbidities;
medical/non-medical; macroeconomic indicators). A data
extraction template was developed and piloted on a ran-
domly selected sample of four included studies. Data were
extracted by one researcher and checked by others. Dis-
agreements were resolved by consensus.
All cost data were converted to purchasing power parity
(PPP)-adjusted US$ 2014 (Int$ 2014) using the Campbell
and Cochrane Economics Methods Group Evidence for
Policy and Practice Information and Coordination Centre
(CCEMG-EPPI Centre) cost converter [23]. When the base
year of the currency was not reported or could not be in-
ferred from the manuscript (e.g. last year of data collection),
it was assumed to be the year before the publication of the
paper. For studies presenting estimates for more than one
year, the most recent estimate was extracted. No adjust-
ments were made to economic outcomes expressed as ra-
tios or percentages e.g. % of GDP.
Analysis
We aggregated and synthesized information on general
study characteristics (geographical setting, care delivery
setting, and pathology), methodological characteristics
(study design, population characteristics, control group,
sample size, dealing with heterogeneity) and economic
burden estimates (currency and year, cost component, cost
perspective). We conducted a narrative synthesis focusing
on the overall economic burden of CVD and hypertension
on households, health systems and the society, as well as
current research gaps. Data were managed and analysed
using Microsoft Excel and R 3.1 statistical software [24].
Role of the funding source
There was no funding source for this study. The corre-
sponding author had full access to all the data in the
study and had final responsibility for the decision to sub-
mit for publication.
Results
The initial search across all seven NCDs returned 64,952
records and 19,646 further records were identified at the
June 2015 update, leading to a total of 84,598 titles.
After excluding the duplicates, 54,137 titles and abstracts
were screened for eligibility and 478 studies potentially
relevant for CVD and hypertension were screened for
full-text. 81 studies met the inclusion criteria and two
further studies were identified through manual searches,
leading to a total of 83 included papers, reporting eco-
nomic estimates for/from 28 countries (Fig. 1). Details
on the included studies together with data extracted
from each full-text source are presented in Add-
itional file 3 and Additional file 4.
Study characteristics
Key study characteristics are summarised in Table 2.
Most studies examined the economic impact of stroke
(29%, n = 24) and 20% of studies looked at generic CVD,
i.e. either unspecified cardiovascular condition(s) or a
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multitude of cardiovascular disorders for which eco-
nomic estimates were reported without disaggregation
by pathology. Secondary care was the most common
study setting: 46% of studies (n = 38) were conducted in
secondary and outpatient care jointly, while 26% (n = 22)
looked at secondary care only and 7% (n = 6) focused on
primary care alone. Five studies included an explicit
non-CVD control group, while the others did not have a
control group.
Most studies were institutional (48%, n = 40), i.e. they
were conducted in either one health facility (40%, n = 33) or
a limited number of facilities (8%, n = 7). The remaining
were nationwide studies (36%, n = 30), within-country re-
gional (11%, n = 9) or others e.g. city or international.
Retrospective cost studies dominated the sample (43%, n =
34) to the detriment of cost-of-illness studies (18%, n = 14),
database analyses (14%, n = 11) or prospective cost studies
(13%, n = 10). The majority of included papers were pub-
lished after 2005 (76%, n = 63). Of the 28 countries for
which at least one economic estimate was available, the
most estimates were reported for China (20%, n = 17), India
(12%, n = 10), Brazil (10%, n = 8) and Mexico (10%, n = 8).
Quality assessment
Table 3 summarizes the quality assessment. Most studies
did not use a sampling method conducive to generalizable
results. In most cases, the quality of the CVD incidence/
prevalence data source (i.e. how CVD was/had been diag-
nosed in study patients) could not be assessed. Two thirds
of the studies included an exploration of uncertainty
and/or heterogeneity in the economic estimates. This
often took the form of regression analysis. Data sources
for expenditure, resource use and unit costs were
clearly presented in 57% (n = 47) of studies. Productiv-
ity costs were included in estimation and cost data
were transparently presented in less than a third of the
included papers. Most studies (n = 29, 35%) reported
costs from the health care provider’s perspective. A patient
and a societal perspective were adopted in 21% (n = 17)
and 22% (n = 18) of studies, respectively. The majority
of studies reported direct costs only. However, 23 stud-
ies also reported estimates of indirect costs. One study
reported the effects of CVD on absenteeism, e.g. number
of productive days lost due to illness, but did not attempt
to calculate indirect costs associated with lost days.
Table 1 Definitions used to categorise included studies
Study design
prospective cost study cost study informed by data gathered from a prospective cohort of patients
retrospective cost study cost study informed by data collected from a retrospective cohort of patients, e.g. medical records, case notes
database analysis analysis of patient records from an already existing database, e.g. health insurance claims, hospital reimbursements
mathematical model mathematical model (+/− simulation) extrapolating primary data to produce original estimates beyond their
original scope e.g. time and location
survey cross-sectional study of patients +/− controls
COI study cost-of-illness study evaluating the region or country-level economic consequences that the presence of disease
and its outcomes exert on individuals and society as a whole
Study scope
Institutional Study conducted in one or more health care facilities, with no specified geographical scope below national level
and no evidence of a sampling procedure to ensure representativeness
City Study conducted in health care facilities in a specified city
Regional Study conducted in health care facilities in a specified sub-national administrative unit (e.g. region, province, state)
National Study conducted at the national level, either through representative sampling of health care facilities or through
modelling
International Multi-country study
Other Other than above or multiple categories
Economic perspective
Patient Study reporting direct costs incurred only by patients (e.g. out-of-pocket payments)
Provider Study reporting costs incurred by the health care provider (e.g. average unit cost of an inpatient day)
Third-party payer Study reporting costs incurred at the level of a third-party payer (e.g. insurance fund, Ministry of Health vertical
programme)
Societal Study reporting some form of indirect cost, incurred at any level (e.g. value of lost productivity due to illness,
effect of CVD on national income)
Other Other perspectives (e.g. pharmaceutical sector) or multiple perspectives (e.g. patient and provider)
Unclear Could not be determined based on the information provided
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Economic findings
We distinguish between economic estimates that refer
to a distinct episode of care and those referring to the
total cost over a specified period, e.g. one month or one
year. In Fig. 2 we present the direct costs (Int$ 2014) per
CVD episode by cardiovascular pathology, economic
perspective (Panel A) and study scope (Panel B). ‘Epi-
sode’ refers here to costs associated with any finite
interaction with a healthcare provider analysed in the
included studies, e.g. consultation, clinic visit or in-
patient stay, usually for acute episodes. The costs per
episode for hypertension and generic CVD were gen-
erally homogeneous across studies, ranging between
$500 and $1500. In contrast, for coronary heart dis-
ease (CHD) and stroke, cost estimates were higher and
more heterogeneous, with several estimates in excess
of $5000 per episode. The economic perspective and scope
of the study appeared to impact cost estimates for hyper-
tension and generic CVD much less than estimates for
stroke and CHD. For example, most institutional-level
stroke studies tended to underestimate direct costs per
episode relative to national-level studies. Studies on stroke
and CHD conducted from the perspective of the patient
tended to estimate higher direct costs than studies taking
the perspective of the provider.
We present direct monthly costs for long-term care in
Fig. 3. For studies which reported costs for time horizons
longer than one month (e.g. six months or one year), we
estimated the monthly cost by dividing the total cost by the
respective number of months, e.g. annual costs were divided
by 12. Most studies reported costs for hypertension, for a
median of $22 per month across estimates. The medians for
average monthly treatment costs for stroke and CHD were
higher, but varied with study scope and economic perspec-
tive from as little as $50 per month (e.g. CHD, patient per-
spective) to over $1000 (e.g. CHD, provider perspective).
However the number of data points for CHD, stroke and
heart failure was much more limited than for hypertension
and variability across estimates was higher.
Table 4 attempts to synthesize the magnitude of the
economic burden for different CVD categories and hyper-
tension, based on the disease categories reported by the
study authors. Studies where a detailed categorization was
not reported, or which grouped several CVD categories to-
gether without reporting separate estimates for each, were
grouped under “generic CVD”. For each country-specific
estimate of the total cost per episode or total annual cost of
care, we calculated the ratio total cost: total health expend-
iture per capita (Int$). For example, the annual direct cost
per patient of hypertension could be as high as 5.9 times
the total health expenditure per capita, with a median ratio
of 0.7. The higher the ratio, the higher the economic
burden of disease. Country-specific ratios are presented
in Additional file 5.
Fig. 1 PRISMA flowchart
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Several studies reported macroeconomic estimates.
Specifically, six studies reported the national or re-
gional economic loss due to CVD in sub-Saharan Africa
[25] ($9bn), Brazil [26] ($ 20bn), India [27] ($2.4 trillion
over 2012–2030), Fiji Islands [28] ($8.5mn), Serbia [29]
($1bn) and China [27] ($8.8trillion over 2012–2030).
One paper used econometric methods to estimate the
global cost of heart failure to be $15.6 billion, however
data from only one LMIC (Brazil) informed the model,
the rest being high-income countries [30]. Four studies
reported the cost of CVD as a proportion of national or
regional GDP: Brazil [26] (1.7%), sub-Saharan Africa
[25] (7%), Russian Federation [31] (2.8%) and Serbia
[29] (1.8%).
Discussion
Summary of findings
We identified a heterogeneous body of literature on the
economic burden of CVD and hypertension in LMICs,
dominated by single centre retrospective cost studies con-
ducted in secondary care settings. The evidence base has
been growing over time, particularly after 2010, and ap-
pears to be concentrated in several countries: studies in
China, Brazil, India and Mexico combined contributed
half the economic results across all included studies.
We identified several gaps in the available literature.
First, a geographical gap: there is a dearth of economic
estimates from sub-Saharan Africa, Central America and
Eastern Europe. This is a concern because the research
does not reflect current and upcoming disease burden
trends. Furthermore, countries with one or two studies
are often informed by data collected in one service provider,
which seriously limits their generalisability and usefulness
for national decision-makers. Second, there is a gap relating
to delivery setting: most studies concentrated on hospital
care, with very few studies including economic aspects of
CVD care in primary and community care. Only two stud-
ies estimated the costs of prevention, one in Mexico [32]
and another in China [33]. Given the importance of preven-
tion and service delivery at these levels, particularly as more
innovative models are being rolled out at these levels in
Table 2 Summary characteristics of included studies (n = 83)
Characteristic/level No. studies (%)
Study scope
Institutional 40 (48)
National 30 (36)
Regional 9 (11)
City 1 (1)
Other 1 (1)
International 2 (1)
CVD category
Stroke 24 (29)
Hypertension 18 (22)
Coronary heart disease 17 (20)
Generic CVD 20 (24)
Heart failure 4 (5)
Care setting
Secondary + outpatient 38 (46)
Secondary 22 (26)
Tertiary 17 (20)
Primary 6 (7)
Study design
Retrospective cost study 34 (43)
Cost-of-illness study 14 (18)
Database analysis 11 (14)
Prospective cost study 10 (13)
Mathematical model 7 (9)
Other 4 (5)
Included a control group [YES] 5 (6)
Economic perspective
Provider 29 (35)
Societal 18 (22)
Patient 17 (21)
Other 10 (12)
Third-party payer 7 (9)
Unclear 1 (1)
Table 3 Summary quality assessment of included studies
Quality criterion Studies (n, %)
Yes No Unclear
Economic component
Data sources for expenditure,
resource use and unit costs
were clearly explained
48 (58%) 34 (42%) n/a
Cost and/or productivity data
were transparently presented
24 (29%) 59 (71%) n/a
Productivity costs were included 23 (28%) 60 (72%) 0 (0%)
If productivity costs included,
results were presented with and
without productivity costs
20 (24%) 3 (4%) n/a
The analysis addressed uncertainty
and/or heterogeneity
53 (64%) 30 (36%) 0 (0%)
Epidemiologic component
The source of incidence/prevalence
data contributed to the study’s
internal validity
35 (42%) 13 (16%) 28 (34%)
The patient sampling method
appropriate for deriving nationwide
estimates of incidence/prevalence
21 (25%) 49 (58%) 9 (11%)
Total number of studies does not add to n = 83 in all criteria because certain
criteria were not applicable in several studies. Please see the Additional file
containing the extraction sheet. n/a - not applicable
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low-resource settings, there would be great value in explor-
ing them as a matter of priority [9]. Third, a research design
gap is also apparent: the majority of the included studies
were retrospective cohorts without a control group and did
not estimate indirect costs, making it difficult to isolate the
economic burden attributable to CVD or hypertension.
This is particularly concerning given the long-term conse-
quences of CVD care for patients and their carers. Finally,
there is also a research quality gap: the quality of the in-
cluded studies was generally low. Reporting transparency,
particularly for cost data sources and results, was poor.
Strengths and limitations
While our findings generally agree with those previous
reviews [34–36], they expand them in several ways: we
go beyond stroke and ischemic heart disease to include
hypertension and heart failure; we find that the annual
cost of care and the cost of an acute episode for patients
with CVD can exceed many times the total health expend-
iture per capita in LMICs; and we distinguish between
the cost of inpatient episodes and the monthly cost of
non-acute care. Methodologically, the value of our re-
view lies in the wide-ranging systematic search strategy,
Fig. 2 Direct medical costs (Int$ 2014) per episode by CVD category (n = 42 studies). 1) For each CVD category and economic perspective (Panel
a) or study scope (Panel b), the boxplot represents cost estimates from individual studies (circles), the sub-group median (vertical line in solid
box), inter-quartile range IQR (distance between lower and upper hinges, which correspond to the first and third quartile) and the upper (lower)
whisker extends from the hinge to the largest (lowest) observed value no further than 1.5 * IQR from the hinge; 2) Three cost estimates ranging
between Int$42,000 and Int$67,000, for very complex interventions in coronary acute syndrome patients (Moleregpoom et al., 2007; Thailand),
were excluded from this Figure for ease of visualization. The median cost estimated in the same study for the simplest coronary acute syndrome
cases is represented
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the absence of language restrictions, the broad time
horizon (1990 onwards), the range of economic per-
spectives considered (from household to societal), the
attempt to synthesize comparatively the economic im-
pact of different pathologies, as well as the quality as-
sessment of included studies. None of the previous
reviews shares all these attributes. We believe our re-
sults provide the first comprehensive picture of the
breadth and quality of economic research into CVD
and hypertension in LMICs.
There are also limitations. First, although we devised
as sensitive a search strategy as possible, we acknow-
ledge there may be grey literature sources that we did
not identify. In the same vein, we did not exclude studies
on quality considerations, which may have led to the over-
all quality of included studies to be lower than warranted.
Nevertheless, we believe there is value in synthesizing in-
formation over the entire body of research at this stage in
order to inform future studies. Second, we excluded eco-
nomic evaluation studies for two types of reasons: meth-
odologically, economic evaluations primarily answer
questions about the relative value of an intervention com-
pared to others. This is a related, but different question
than the one addressed in this review. While economic
evaluations may contain useful economic information, we
anticipated difficulties in ascertaining from the papers’
full-text the extent to which the comparator or the inter-
vention(s) in economic evaluations were (or would
Fig. 3 Monthly direct medical costs (Int$ 2014) by CVD category (n = 31 studies). For each CVD category and economic perspective (Panel a) or
study scope (Panel b), the boxplot represents cost estimates from individual studies (circles), the sub-group median (vertical line in solid box),
inter-quartile range IQR (distance between lower and upper hinges, which correspond to the first and third quartile) and the upper (lower)
whisker extends from the hinge to the largest (lowest) observed value no further than 1.5 * IQR from the hinge
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become) part of current practice, which would have been
of key interest given our aim to describe the current eco-
nomic burden of disease. Pragmatically, the fast growing
number of economic evaluations conducted in LMICs
during the past decade would have overburdened the re-
view process, as well as interpreting the results. Third, we
excluded studies reporting the economic burden of CVD
risk factors other than hypertension.
Implications
Our results highlight that annual costs of CVD care signifi-
cantly exceed health expenditure per capita in most LMICs,
raising the issues of financial protection for CVD patients
and, more broadly, of health financing sustainability. Health
financing reform as part of progress towards universal
health coverage will have to mean more than mobilising
additional funding and managing transition from donor
support; it will have to strengthen the role of pre-paid con-
tributions, effective pooling and strategic purchasing if
health systems are to cope with the rising burden of CVD
and NCDs at large. Caution is warranted in relation to the
magnitude of our findings, however. Pooling together eco-
nomic estimates from such heterogeneous, poor quality
studies can only offer an indication of the true magnitude
of the burden. Country-specific results of higher methodo-
logical quality are needed to inform national planning and
decision-making.
Our findings confirm those of previous studies suggesting
that the current evidence on the economic burden of CVD
in LMICs does not appear aligned with policy priorities in
terms of volume, focus and methodological quality [37].
More economic research of better methodological quality
needs to be conducted in areas with current gaps, specific-
ally: i) in community and primary care settings; ii) incorpor-
ating an appropriate control group; iii) collecting data from
multiple sites with a view to representativeness; and iv)
incorporating the full economic consequences of CVD
prevention and care, not merely direct medical costs. More
broadly, the rationale of conducting cost studies, as are the
majority of studies included in this review, will require an
increasingly clear and strong justification. While these
are useful to estimate the costs of CVD interventions
and to quantify household-level economic burden, they
have limited value for policy compared to national-level
cost-of-illness studies. In countries where reliable cost
estimates of CVD interventions are missing, good quality
cost studies will likely continue to be necessary with a
view to informing credible cost-of-illness and health sector
planning exercises. In countries where cost estimates
are already available, methodological quality will need
to improve hand in hand with a shift in research de-
signs towards answering questions of interest to na-
tional policy makers.
The main reasons for the scarcity and low quality
economic data in LMICs on the impact of NCDs more
broadly and of CVD specifically are well known. There
is still insufficient capacity and ownership for health
systems and health economics research in LMICs [38, 39].
Despite long-standing international interest in research
capacity strengthening [40, 41] with some promising re-
sults [42, 43], good practice recommendations in this area
are relatively recent [44–46]. Second, before their explicit
inclusion in the Sustainable Development Goals (Target
3.4 “reduce by one third premature mortality from NCDs
through prevention and treatment, and promote mental
health and wellbeing”), NCDs received insufficient atten-
tion from national governments relative to the yet unfin-
ished agenda of infectious diseases. From an international
development perspective, NCDs have received a dispropor-
tionately (albeit increasing) small amount of donor funding
relative to their burden compared to other global health
areas, despite countries’ requests for funding NCD pro-
grammes [47]. Although donor support can and should
improve in the future, national governments will still need
to identify solutions to fund NCD interventions and reduce
the current burden. In this context, better quality eco-
nomic data on the burden of CVD are necessary for build-
ing strong investment cases to national health decision
makers towards investing in CVD prevention and treat-
ment. While acknowledging that economic considerations
are just one type of consideration in policy decisions [39],
they still need to be explicit and robust if they are to be
considered at all.
Conclusions
We assessed and synthesized the evidence of CVD and
hypertension economic impact across a wide range of
economic outcomes and study designs, thereby offering
the first comprehensive and systematic picture of research
in the field. The economic impact of CVD and hyperten-
sion appears to be substantial relative to current health
Table 4 Ratio of total cost of care to country-specific total
health expenditure per capita (Int$), summary statistics
NCD category Min Median Max No studies
Annual cost of care
coronary heart disease 1.46 10.02 27.83 5
generic CVD 0.01 0.96 3.29 4
chronic heart failure 5.59 9.41 56.98 3
hypertension 0.01 0.68 5.89 10
stroke 1.48 12.70 472.48 9
Cost per episode
coronary heart disease 0.26 12.73 143.38 14
generic CVD 0.17 4.07 47.20 4
hypertension 0.09 3.84 52.63 8
stroke 0.72 10.44 497.06 16
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expenditure levels. Further research into the economic
impact of CVD and hypertension is needed in many LMICs
to inform appropriate NCD policies, with due focus on
improving the quality of research and aligning research
outputs with demonstrated disease burden. More broadly,
national-level studies with appropriate sample sizes and
adequate incorporation of indirect costs need to replace
small-scale, institutional, retrospective cost studies.
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